Assay for ppm Levels of Azide in Drug Substances - - Chromatography Online
Assay for ppm Levels of Azide in Drug Substances


LCGC North America
Volume 30, Issue 11, pp. 986-991

The removal of azide as a potential impurity from a drug substance may be critical to its safety profile, such that quantitation of this impurity becomes an important control parameter. This paper describes a simple and practical assay for azide using chemical derivatization and high performance liquid chromatography. The method is shown to be suitable for the intended purpose on three example test materials. Potential issues for wider applications are discussed.

In the manufacturing of pharmaceutical drug substances in which azides are used as reagents or when they are generated somehow in the synthesis, it may be necessary to demonstrate that these impurities are sufficiently removed to levels below an appropriate safety threshold. The threshold would depend on the target dose and route of administration. Sodium azide is an example of an azide for which the environmental exposure limits have been reasonably well characterized (1). Testing for azides can be performed on the final drug substance, but may also be performed at critical control points in a synthesis such as with related compounds like starting materials and intermediates.


Figure 1: PFBB– azide derivatization reaction
This article describes the use of pentafluorobenzyl bromide (PFBB) as a derivatization agent to form the pentafluorobenzyl-azide (PFB-Az) derivative, based on a known approach for synthesizing azides (2,3) as diagrammed in Figure 1.

Relative to azide, the derivative can be easily detected by UV absorbance detection and is sufficiently nonpolar for retention on conventional reversed-phase high performance liquid chromatography (HPLC) analytical columns. Thus, there is potential to manage this reaction for application to parts-per-million analysis of azide as an impurity in drug substances and related compounds.

The literature describes the assay of azide in different modes, such as using ion-based HPLC (4–6), derivatization-based gas chromatography (GC) (7,8), and derivatization-based HPLC (9,10). The reagent PFBB has been used in conjunction with GC analysis (7,8), and other derivatization agents have been used in conjunction with HPLC analysis (9,10).

This article covers the assay of free azide, based on the use of sodium azide as the standard and spiking agent in method development. The work described herein is on three drug substance–related compounds exhibiting a range of polarity and complexity. Because of their proprietary nature, the three materials of interest will be designated as compounds A, B, and C, where A is the most polar with the smallest molecular size, and C is the least polar with the largest molecular size.

Experimental

Materials

Sodium azide, pentafluorobenzylbromide (PFBB), dimethyl sulfoxide (DMSO), trifluoroacetic acid, and acetonitrile were obtained from Sigma-Aldrich. Distilled deionized water was obtained through an in-house purification system.

Azide Standard and Test Sample Preparation

Azide standards were prepared using sodium azide in DMSO, in which target parts-per-million concentrations were set relative to free azide concentration. Test samples of compounds A, B, and C were prepared at a 10-mg/mL target concentration in DMSO.

Derivatization Conditions

A PFBB stock solution was first prepared by transferring 100 μL of PFBB to a 5-mL volumetric flask, then the substance was diluted to flask volume with DMSO, and the contents were mixed well. When 100 μL of this stock was added to a 5-mL volume of a standard or test sample solution, taking into account density and concentrations, the PFBB was present at 10-fold molar equivalents in excess over 1000 ppm free azide. A derivatized blank was prepared in a similar fashion in which 100 μL of the PFBB stock solution was added to 5 mL of DMSO. The derivatization had no quenching procedure, but it was shown that the reaction, whether for standards or test samples, required ~4–6 h to reach completion, and that the solutions exhibited no significant changes in HPLC profiles after at least 16 h in ambient conditions.

Chromatographic Analysis Conditions


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters
Global E-newsletters subscribe here:




 

LCGC COLUMNISTS 2014

Column Watch: Ron Majors, established authority on new column technologies, keeps readers up-to-date with new sample preparation trends in all branches of chromatography and reviews developments. LATEST: When Bad Things Happen to Good Food: Applications of HPLC to Detect Food Adulteration


Perspectives in Modern HPLC: Michael W. Dong is a senior scientist in Small Molecule Drug Discovery at Genentech in South San Francisco, California. He is responsible for new technologies, automation, and supporting late-stage research projects in small molecule analytical chemistry and QC of small molecule pharmaceutical sciences. LATEST: HPLC for Characterization and Quality Control of Therapeutic Monoclonal Antibodies


MS — The Practical Art: Kate Yu brings her expertise in the field of mass spectrometry and hyphenated techniques to the pages of LCGC. In this column she examines the mass spectrometric side of coupled liquid and gas-phase systems. Troubleshooting-style articles provide readers with invaluable advice for getting the most from their mass spectrometers. LATEST: Radical Mass Spectrometry as a New Frontier for Bioanalysis


LC Troubleshooting: LC Troubleshooting sets about making HPLC methods easier to master. By covering the basics of liquid chromatography separations and instrumentation, John Dolan is able to highlight common problems and provide remedies for them. LATEST: How Much Can I Inject? Part I: Injecting in Mobile Phase


More LCGC Columnists>>

LCGC North America Editorial Advisory Board>>

LCGC Europe Editorial Advisory Board>>

LCGC Editorial Team Contacts>>


Source: LCGC North America,
Click here